Potential lack of standing could end Myriad case with no DNA patent resolution
This article was originally published in Scrip
Executive Summary
When a three-judge panel from the US Court of Appeals for the Federal Circuit hears oral arguments 4 April in Washington in a case examining whether isolated DNA is patentable, the court must first decide whether the plaintiffs in the case against Myriad Genetics actually have standing to bring the suit.